batoprotafib + nazartinib

Batoprotafib + nazartinib is an investigational oral combination therapy being studied for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC). Batoprotafib (TNO155) is a selective small molecule inhibitor of SHP2, a protein tyrosine phosphatase involved in RAS/MAPK pathway signaling. Nazartinib (EGF816) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), designed to target activating and resistance mutations in EGFR. The rationale for combining these agents is to block parallel or compensatory signaling pathways that drive tumor growth and resistance mechanisms. This combination has been evaluated in early-phase clinical trials to assess safety, tolerability, and preliminary antitumor activity in patients with advanced solid tumors harboring relevant molecular alterations[1][3][4][5][8].

Other names

batoprotafib + EGF816TNO155 + nazartinib